90% of GLP-1 Users Access Drugs Without Dietary or Psychological Support
"We know that over 90% of people who access these drugs do so outside of a complete support system. So they don't have exercise support, psychological support, and most importantly, dietary support. That is a problem."
About this episode
On this episode of Zoe: Science and Nutrition, host Jonathan Wolf interviewed Dr. Federica Amati, Zoe's head nutritionist and scientist at Imperial College London, about the explosion of GLP-1 weight loss medications and the largely unaddressed nutritional crisis surrounding their use. With 1 in 10 Americans already trying drugs like Ozempic, Mounjaro, and Wegovy, Amati revealed that over 90% access these medications without proper dietary, exercise, or psychological support frameworks, creating widespread risks of micronutrient deficiencies, muscle wasting, and rebound weight gain worse than pre-treatment levels. The conversation centered on Amati's new book 'The Appetite Reset,' which provides specific nutrition protocols for three phases: pre-treatment preparation focusing on gut microbiome health and fiber intake to reduce side effects; during-treatment emphasis on nutrient density, protein intake, hydration, and resistance training; and post-treatment tapering with high-volume, high-fiber foods to maintain fat loss. Amati disclosed that two-thirds of users stop within one year due to intolerable gastrointestinal side effects that are actually manageable through diet, and presented case studies including a UK patient who developed scurvy and another with dementia-like symptoms from severe nutrient depletion. She explained how the drugs work by mimicking GLP-1 hormones that slow stomach emptying and signal the brain to suppress hunger, eliminating what she termed 'food noise'—the obsessive mental preoccupation with food that parallels eating disorder pathology. Wolf and Amati emphasized these are metabolic disease medications, not cosmetic weight loss tools, and stressed that without lifestyle changes, users risk sarcopenic obesity where lost weight returns primarily as fat rather than muscle. The episode provided actionable guidance on protein sources beyond red meat, the critical role of gut microbiome in appetite regulation, and why some patients successfully maintain weight loss after cessation while others rapidly regain.
Key takeaways
- Over 90% of people taking GLP-1 drugs like Ozempic access them without proper dietary, exercise, or psychological support systems.
- Two-thirds of GLP-1 users stop within one year primarily due to gastrointestinal side effects that are manageable through proper diet.
- Stopping GLP-1s abruptly causes weight regain predominantly as fat not muscle, creating sarcopenic obesity with worse metabolic health than baseline.
- A UK patient developed scurvy while on weight loss drugs unsupervised, and another showed dementia-like symptoms from micronutrient deficiencies.
- GLP-1 drugs eliminate 'food noise'—persistent obsessive thoughts about food—which patients value more than the weight loss itself.
- Preparing gut microbiome with high-fiber diet before starting GLP-1s significantly reduces nausea, constipation, and vomiting side effects.
- During treatment, protein needs increase to 1.2-1.6 grams per kilogram body weight, but resistance training is non-negotiable to prevent muscle loss.